Patents Assigned to Tufts Medical Center, Inc.
-
Publication number: 20190255302Abstract: Systems and methods and devices are provided for arresting or reversing the effects of myocardial remodeling and degeneration after cardiac injury, without the potential drawbacks associated with previously existing systems and methods, by at least partially occluding flow through the superior vena cava over multiple cardiac cycles, and more preferably, by adjusting the interval or degree of occlusion responsive to a sensed level of patient activity. In some embodiments, a controller is provided that actuates a drive mechanism responsive to a sensed level of patient activity to provide at least partial occlusion of the patient's superior vena cava, while a data transfer circuit of the controller provides bi-directional transfer of physiologic data to the patient's smartphone or tablet to permit display and review of such data.Type: ApplicationFiled: May 2, 2019Publication date: August 22, 2019Applicant: Tufts Medical Center, Inc.Inventors: Navin K. KAPUR, Richard H. KARAS
-
Patent number: 10279152Abstract: Systems and methods and devices are provided for arresting or reversing the effects of myocardial remodeling and degeneration after cardiac injury, without the potential drawbacks associated with previously existing systems and methods, by at least partially occluding flow through the superior vena cava over multiple cardiac cycles, and more preferably, by adjusting the interval or degree of occlusion responsive to a sensed level of patient activity. In some embodiments, a controller is provided that actuates a drive mechanism responsive to a sensed level of patient activity to provide at least partial occlusion of the patient's superior vena cava, while a data transfer circuit of the controller provides bi-directional transfer of physiologic data to the patient's smartphone or tablet to permit display and review of such data.Type: GrantFiled: July 6, 2016Date of Patent: May 7, 2019Assignee: Tufts Medical Center, Inc.Inventors: Navin K. Kapur, Richard H. Karas
-
Publication number: 20190126014Abstract: Systems and methods and devices are provided for treating conditions such as heart failure and/or pulmonary hypertension by at least partially occluding flow through the superior vena cava for an interval spanning multiple cardiac cycles. A catheter with an occlusion device is provided along with a controller that actuates a drive mechanism to provide at least partial occlusion of the patient's superior vena cava, which reduces cardiac filling pressures, and induces a favorable shift in the patient's Frank-Starling curve towards healthy heart functionality and improved cardiac performance. The occlusion device may include a lumen obstructed by a relief valve that may permit fluid flow through the occlusion device to release an excessive build-up of pressure.Type: ApplicationFiled: October 23, 2018Publication date: May 2, 2019Applicant: Tufts Medical Center, Inc.Inventors: Navin K. KAPUR, Richard H. KARAS
-
Patent number: 10258284Abstract: An implant sized and shaped to be endovascularly delivered to the middle meningeal artery includes a carrier that carries a payload between first and second ends thereof. An anchor mechanism associated with the implant transitions into a swollen state in response to exposure to bodily fluids. In the swollen state, said anchor mechanism anchors the implant to the middle meningeal artery. Before or during the transition, the anchor mechanism permits endovascular delivery of the implant to the middle meningeal artery.Type: GrantFiled: April 5, 2018Date of Patent: April 16, 2019Assignee: Tufts Medical center, Inc.Inventors: Adel M. Malek, Carl Heilman
-
Patent number: 10214590Abstract: Endoglin has been identified to play a functional role as a regulator of TGF?1 signaling, particular in TGF?1-mediated calcineurin expression. The present invention features methods of reducing cardiac damage, particularly in a subject undergoing chemotherapy or radiation therapy by administering a composition that inhibits endoglin activity. The present invention also features methods of treating autoimmune diseases, inflammatory diseases, organ transplantation, and conditions association with oxidative stress related to TGF?1-mediated calcineurin expression and reactive oxygen species (ROS) production by administering a composition that inhibits endoglin activity. The present invention also features methods of treating fibrotic diseases by administering a composition that inhibits endoglin activity.Type: GrantFiled: September 18, 2014Date of Patent: February 26, 2019Assignee: Tufts Medical Center, Inc.Inventors: Navin K. Kapur, Richard H. Karas
-
Publication number: 20190000885Abstract: Aspects of the technology disclosed herein generally (and in part) relates to use of Angiogenin (ANG) for increasing hematopoietic reconstitution of in vivo hematopoietic cells and transplanted hematopoietic cells. Provided herein are methods and compositions useful in treatment of diseases characterized by decreased levels of hematopoietic cells, decreased levels of hematopoietic reconstitution, blood cell deficiency and prevention and treatment of radiation injury. One aspect relates to angiogenin treated hematopoietic cell compositions and methods of their use in stem cell transplantation. Treatment of hematopoietic cells with angiogenin enhances quiescence and reduces proliferative capacity of primitive hematopoietic stem cells while increasing proliferation of myeloid restricted progenitor cells. Another aspect relates to use of ANG in prophylactic and therapeutic treatment methods for radiation injury.Type: ApplicationFiled: November 29, 2016Publication date: January 3, 2019Applicants: THE GENERAL HOSPITAL CORPORATION, TUFTS MEDICAL CENTER, INC., TRUSTEES OF TUFTS COLLEGE, PRESIDENT AND FELLOWS OF HARVARD COLLEGEInventors: David SCADDEN, Peter KHARCHENKO, Lev SILBERSTEIN, Guo-fu HU, Kevin GONCALVES
-
Patent number: 10112036Abstract: An endovascular implantable shunt device for draining cerebrospinal fluid from a patient's subarachnoid space includes a shunt having opposed first and second ends, a one-way valve located at the first end of the shunt, a helical tip disposed at the second end, and a hollow passageway extending between the helical tip and one-way valve. The helical tip is constructed to penetrate a patient's sinus wall. Cerebrospinal fluid drains through the helical tip and out through the valve.Type: GrantFiled: October 22, 2015Date of Patent: October 30, 2018Assignee: Tufts Medical Center, Inc.Inventors: Carl Heilman, Adel M. Malek
-
Patent number: 10106834Abstract: Methods for the diagnosis and treatment of B cell Acute Lymphoblastic Leukemia (B-ALL), based in part on the detection and/or inhibition of Focal Adhesion Kinase (FAK), e.g., phosphorylated FAK (pFAK).Type: GrantFiled: October 9, 2014Date of Patent: October 23, 2018Assignees: The General Hospital Corporation, Tufts Medical Center, Inc.Inventors: Katia Georgopoulos, Richard A. Etten, Ila Joshi
-
Publication number: 20180243541Abstract: Systems and methods and devices are provided for arresting or reversing the effects of myocardial remodeling and degeneration after cardiac injury, without the potential drawbacks associated with previously existing systems and methods, by at least partially occluding flow through the superior vena cava over multiple cardiac cycles, and more preferably, by adjusting the interval or degree of occlusion responsive to a sensed level of patient activity. In some embodiments, a controller is provided that actuates a drive mechanism responsive to a sensed level of patient activity to provide at least partial occlusion of the patient's superior vena cava, while a data transfer circuit of the controller provides bi-directional transfer of physiologic data to the patient's smartphone or tablet to permit display and review of such data.Type: ApplicationFiled: August 15, 2016Publication date: August 30, 2018Applicant: Tufts Medical Center, Inc.Inventors: Navin K. KAPUR, Richard H. KARAS
-
Patent number: 9878054Abstract: In certain embodiments, this disclosure relates to pharmaceutical formulations for polypeptide and lipophilic moiety conjugates suitable for injection into humans and other animals and methods of preparation. In certain embodiments, the disclosure relates to a method of preparing the formulation comprising lyophilizing, solubilizing in ammonium acetate, filtering to create mono-disperse particles, re-lyophilizing, and solubilizing the micelles in a dextrose solution for injection.Type: GrantFiled: May 17, 2013Date of Patent: January 30, 2018Assignee: Tufts Medical Center, Inc.Inventor: Athan Kuliopulos
-
Patent number: 9737696Abstract: Implantable shunt devices and methods for draining cerebrospinal fluid from a patient's subarachnoid space include a shunt having opposed first and second ends, the second end being constructed to penetrate a wall of a sigmoid, transverse, straight, or sagittal sinus of the patient, a one-way valve, a hollow passageway extending between the second end and the one-way valve such that cerebrospinal fluid can be drained through the second end and out through the valve, and a mechanism coupled to the shunt and configured to anchor the shunt at a desired location proximal to the subarachnoid space.Type: GrantFiled: January 14, 2015Date of Patent: August 22, 2017Assignee: Tufts Medical Center, Inc.Inventors: Carl Heilman, Adel M. Malek
-
Patent number: 9737697Abstract: An endovascular implantable shunt device for draining cerebrospinal fluid from a patient's subarachnoid space includes a shunt having opposed first and second ends, a one-way valve located at the first end of the shunt, a tip disposed at the second end, and a hollow passageway extending between the tip and one-way valve. The tip is constructed to penetrate a patient's sinus wall. Cerebrospinal fluid drains through the tip and out through the valve.Type: GrantFiled: October 14, 2016Date of Patent: August 22, 2017Assignee: Tufts Medical Center, Inc.Inventors: Carl Heilman, Adel M. Malek
-
Patent number: 9662314Abstract: Disclosed are methods of treating a muscle disease and improving normal muscle function by administering a therapeutically effective amount of an isoprenoid antibiotic. Also disclosed are methods of upregulating hnRNP L and hnRNP L targets by administering a therapeutically effective amount of an isoprenoid antibiotic. Methods of screening compounds for use in treating muscle disease and improving muscle function are also described.Type: GrantFiled: October 19, 2012Date of Patent: May 30, 2017Assignees: Tufts Medical Center, Inc., Children's Medical Center CorporationInventors: Isabelle Draper, Louis M. Kunkel, Matthew S. Alexander, Alan S. Kopin
-
Patent number: 9642994Abstract: Implantable shunt devices and methods for draining cerebrospinal fluid from a patient's subarachnoid space include a shunt having opposed first and second ends, the second end being constructed to penetrate a wall of a sigmoid, transverse, straight, or sagittal sinus of the patient, a one-way valve, a hollow passageway extending between the second end and the one-way valve such that cerebrospinal fluid can be drained through the second end and out through the valve, and a mechanism coupled to the shunt and configured to anchor the shunt at a desired location proximal to the subarachnoid space.Type: GrantFiled: January 14, 2015Date of Patent: May 9, 2017Assignee: TUFTS MEDICAL CENTER, INC.Inventors: Carl Heilman, Adel M. Malek
-
Publication number: 20170065668Abstract: Matrix metalloproteases (MMPs) play many important roles in normal and pathological remodeling processes including atherothrombotic disease, inflammation, angiogenesis and cancer. This invention relates to the activation of protease-activated receptor-1 (PAR-1) by endogenous platelet MMP-1 collagenase on the surface of platelets. Exposure of platelets to fibrillar collagen converts the surface-bound pro-MMP-1 zymogen to active MMP-1, which promotes aggregation through PAR-1. MMP-1 is shown to cleave the PAR-1 extracellular domain at a novel site, which then strongly activates Rho-GTP signaling pathways, cell shape change and motility, and MAPK signaling. Blockade of MMP-PAR1 suppresses thrombogenesis under arterial flow conditions and inhibited thrombosis in animals. These studies provide a link between matrix-dependent activation of metalloproteases and platelet-G protein signaling and identify MMP-1/PAR-1 as a new target for the treatment and prevention of arterial thrombosis and other thrombotic diseases.Type: ApplicationFiled: May 26, 2016Publication date: March 9, 2017Applicant: Tufts Medical Center, Inc.Inventors: Athan Kuliopulos, Georgios Koukos
-
Publication number: 20170049946Abstract: Systems and methods and devices are provided for arresting or reversing the effects of myocardial remodeling and degeneration after cardiac injury, without the potential drawbacks associated with previously existing systems and methods, by at least partially occluding flow through the superior vena cava over multiple cardiac cycles, and more preferably, by adjusting the interval or degree of occlusion responsive to a sensed level of patient activity. In some embodiments, a controller is provided that actuates a drive mechanism responsive to a sensed level of patient activity to provide at least partial occlusion of the patient's superior vena cava, while a data transfer circuit of the controller provides bi-directional transfer of physiologic data to the patient's smartphone or tablet to permit display and review of such data.Type: ApplicationFiled: July 6, 2016Publication date: February 23, 2017Applicant: Tufts Medical Center, Inc.Inventors: Navin K. KAPUR, Richard H. KARAS
-
Patent number: 9468666Abstract: Endoglin has now been shown to be an important target of therapy to reduce disease symptoms associated with heart failure, particularly cardiac fibrosis. Soluble Endoglin is identified as an anatogonist to TGF?1 activity, while membrane-bound Endoglin is identified as a necessary component to promote TGF?1 activity in heart failure. The present invention therefore features methods and kits for treatment of subject having heart failure or a related disorder by administering a composition that decreases TGF?1 signaling through either direct inhibition of membrane-bound Endoglin or promoting expression of soluble Endoglin.Type: GrantFiled: July 31, 2012Date of Patent: October 18, 2016Assignee: Tufts Medical Center, Inc.Inventors: Navin K. Kapur, Richard H. Karas
-
Patent number: 9393384Abstract: Systems and methods and devices are provided for arresting or reversing the effects of myocardial remodeling and degeneration after cardiac injury, without the potential drawbacks associated with previously existing systems and methods, by at least partially occluding flow through the superior vena cava over multiple cardiac cycles, and more preferably, by adjusting the interval or degree of occlusion responsive to a sensed level of patient activity. In some embodiments, a controller is provided that actuates a drive mechanism responsive to a sensed level of patient activity to provide at least partial occlusion of the patient's superior vena cava, while a data transfer circuit of the controller provides bi-directional transfer of physiologic data to the patient's smartphone or tablet to permit display and review of such data.Type: GrantFiled: August 17, 2015Date of Patent: July 19, 2016Assignee: Tufts Medical Center, Inc.Inventors: Navin K. Kapur, Richard H. Karas
-
Patent number: 9376499Abstract: Matrix metalloproteases (MMPs) play many important roles in normal and pathological remodeling processes including atherothrombotic disease, inflammation, angiogenesis and cancer. This invention relates to the activation of protease-activated receptor-1 (PAR-1) by endogenous platelet MMP-1 collagenase on the surface of platelets. Exposure of platelets to fibrillar collagen converts the surface-bound pro-MMP-1 zymogen to active MMP-1, which promotes aggregation through PAR-1. MMP-1 is shown to cleave the PAR-1 extracellular domain at a novel site, which then strongly activates Rho-GTP signaling pathways, cell shape change and motility, and MAPK signaling. Blockade of MMP-PAR1 suppresses thrombogenesis under arterial flow conditions and inhibited thrombosis in animals. These studies provide a link between matrix-dependent activation of metalloproteases and platelet-G protein signaling and identify MMP-1/PAR-1 as a new target for the treatment and prevention of arterial thrombosis and other thrombotic diseases.Type: GrantFiled: August 14, 2014Date of Patent: June 28, 2016Assignee: Tufts Medical Center, Inc.Inventors: Athan Kuliopulos, Georgios Koukos
-
Patent number: 9353188Abstract: Disclosed herein are novel compositions and methods for the inhibition of Plexin B2-mediated Angiogenin activity. Such compositions and methods are useful, for example, for the treatment of cancer, the treatment of wet AMD and the inhibition of angiogenesis. Also disclosed herein are methods of determining whether a test agent is a modulator of Plexin B2 activity.Type: GrantFiled: March 28, 2012Date of Patent: May 31, 2016Assignees: President and Fellows of Harvard College, Tufts Medical Center, Inc.Inventors: Guofu Hu, Wenhao Yu